Defining the Role of Optical Super-high Magnification Dermoscopy in the Diagnosis of Skin Tumors (OSHMD)
A Prospective Observational Study for Defining the Role of Optical Super-high Magnification Dermoscopy in the Diagnosis of Skin Tumors
Study Overview
Status
Status
Conditions
Conditions
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- patients who will come to our attention for skin cancer screening with dermoscopy, willing to partecipate to the study
Exclusion Criteria:
- patients aged under 18 year old
- patients unable to understand and signed the onformed consent
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Evaluate the diagnostic accuracy and clinical utility of super-high magnification dermoscopy in the detection and differentiation of skin tumors
Time Frame: from the enrollment to the reaching of 1000 patients or up to 156 weeks
|
Accuracy (sensibility and specificity) of dermoscopy 400x for detecting skin tumors (vs histopathological diagnosis)
|
from the enrollment to the reaching of 1000 patients or up to 156 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Estimated)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- CET 58-2025 (OSHMD)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Cancers
-
NCT01843725CompletedMetastatic Colorectal Cancers | Metastatic Gastric Cancers | Metastatic Oesophageal Cancers | Metastatic Pancreatic Cancers | Metastatic Biliary Cancers | Metastatic Breast Cancers
-
NCT02751151CompletedNonmelanoma Skin Cancers
-
NCT04112342Suspended
-
NCT02792465Active, not recruitingBreast Cancer | Advanced Solid Cancers
-
NCT05940948WithheldSkin Cancer | Skin Lesion | Skin Melanoma | Skin Cancer, Non-Melanoma | Skin Cancers - Squamous Cell Carcinoma | Skin Cancers - Basal Cell Carcinoma
-
NCT02045368CompletedMelanoma | Breast Cancer | Brain Cancer | Head and Neck Cancers | Gastrointestinal Cancers | Gynecologic Cancers | Genitourinary Cancers | Thoracic Cancers
-
NCT07406789Not yet recruiting
-
NCT05855265CompletedHead and Neck Cancers - Nasopharyngeal
-
NCT05035745RecruitingAdvanced Refractory Solid Tumors | Advanced Triple Negative Breast Cancers | Metastatic Triple Negative Breast Cancers
-
NCT06409195Recruiting